Hall David J, Belli Erol V, Gregg Jon A, Salgado Juan C, Baz Maher A, Staples E Denmark, Beaver Thomas M, Machuca Tiago N
Division of Thoracic and Cardiovascular Surgery, University of Florida College of Medicine, Gainesville, Florida.
Division of Transplant Nephrology, University of Florida College of Medicine, Gainesville, Florida.
Ann Thorac Surg. 2017 Apr;103(4):1076-1083. doi: 10.1016/j.athoracsur.2016.09.107. Epub 2016 Dec 22.
Lung retransplantation (ReTx) comprises an increasing share of lung transplants and recently has shown improved outcomes. The aim of this study was to identify risk factors affecting overall survival after pulmonary ReTx.
The United Network for Organ Sharing database was used to identify patients undergoing lung transplantation at our institution from 1995 to 2014. Of the total 542 lung transplants performed, 87 (16.1%) were ReTxs. The primary outcome was overall survival. Multivariate Cox regression models were used to assess the effect of recipient and donor characteristics on survival.
Of the patients who underwent ReTx, median survival was 2 years. Predictors of worse survival include recipient age between 50 and 60 years (relative risk, 4.3; p = 0.02) or older than 60 years (relative risk, 10.2; p < 0.001), and time to ReTx of less than 2 years (relative risk, 3.8; p = 0.01). ReTx for bronchiolitis obliterans syndrome had longer median survival than for restrictive chronic lung allograft dysfunction (2.7 years vs 0.9 years; p = 0.055). Overall survival of ReTx patients after initiation of the lung allocation score was not significantly different (p = 0.21).
Lung ReTx outcomes are significantly worse than for primary transplantation but may be appropriate in well-selected patients with certain diagnoses. Lung ReTx in patients older than 50 years or within 2 years of primary lung transplantation was associated with decreased survival. Further work is warranted to identify patients who benefit most from ReTx.
肺再次移植(ReTx)在肺移植中所占比例日益增加,且近期显示出更好的预后。本研究的目的是确定影响肺再次移植后总体生存的危险因素。
使用器官共享联合网络数据库来识别1995年至2014年在我们机构接受肺移植的患者。在总共进行的542例肺移植中,87例(16.1%)为再次移植。主要结局是总体生存。采用多变量Cox回归模型评估受者和供者特征对生存的影响。
接受再次移植的患者中,中位生存期为2年。生存较差的预测因素包括受者年龄在50至60岁之间(相对风险,4.3;p = 0.02)或大于60岁(相对风险,10.2;p < 0.001),以及再次移植时间少于2年(相对风险,3.8;p = 0.01)。闭塞性细支气管炎综合征的再次移植中位生存期比限制性慢性肺移植功能障碍更长(2.7年对0.9年;p = 0.055)。肺分配评分开始后再次移植患者的总体生存无显著差异(p = 0.21)。
肺再次移植的结局明显比初次移植差,但对于某些诊断明确且经过精心挑选的患者可能是合适的。50岁以上或初次肺移植后2年内进行肺再次移植的患者生存降低。有必要进一步开展工作以确定最能从再次移植中获益的患者。